Skip to main
AKTX
AKTX logo

Akari Therapeutics (AKTX) Stock Forecast & Price Target

Akari Therapeutics (AKTX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Akari Therapeutics PLC is developing a promising oncology product candidate, AKTX-101, which has shown significant preclinical activity against various solid tumors, particularly in combination with immuno-oncology agents. The company's novel antibody-drug conjugate platform, which utilizes proprietary cancer-killing toxins, demonstrates potential for enhanced efficacy and safety, representing a transformative advancement in cancer therapies. Additionally, the ability of AKTX-101 to generate immunological memory against tumors suggests a strong synergy with existing treatments, underscoring a potentially best-in-class therapeutic profile in the competitive oncology landscape.

Bears say

Akari Therapeutics PLC's outlook is negatively affected by its weak balance sheet, which poses a considerable risk to its financial stability. The company faces a potential financial overhang that could impact its stock, particularly as it requires additional funding to support ongoing and planned preclinical and clinical programs. Without securing these necessary funds, the company's financial challenges may continue to weigh heavily on its stock performance.

Akari Therapeutics (AKTX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Akari Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Akari Therapeutics (AKTX) Forecast

Analysts have given Akari Therapeutics (AKTX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Akari Therapeutics (AKTX) has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Akari Therapeutics (AKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.